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Fig. 5; Jacquet et al., 2015) and in vivo (Fig. 4; Jacquet et al., 2015).
Validation for sterility and speciﬁc and non-speciﬁc human
pathogens conﬁrmed that the cells in Master Bank were sterile,
mycoplasma-free, and negative for human immunodeﬁciency virus 1
(HIV-1), Human T-lymphotropic virus type 1 (HTLV-1), hepatitis B
and C (HBV and HCV), human herpes simplex virus HHV-4 (Epstein–
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Materials and methods
Consenting process
We distribute patient information sheets (PIS) and consent forms to
the in vitro fertilization (IVF) patients if they opted to donate to research
embryos that were stored for 5 or 10 years. They mail signed consent
back to us and that might be months after the PIS and consent were
mailed to them. If in themeantime new versions of PIS/consent are im-
plemented, we do not send these to the patients or ask them to re-sign;
thewhole process is donewith the version thatwas given them initially.
The PIS/consent documents (PGD-V.9) were created on Feb. 09, 2011.
HFEA Code of Practice that was in effect at the time of document crea-
tion: Edition 8—R.2 (http://www.hfea.gov.uk/2999.html). The donor
couple signed the consent on Jul. 21, 2011. HFEA Code of Practice that
was in effect at the time of donor signature: Edition 8—R.3. HFEA Code
of Practice Edition 8—R.2 was in effect: Apr. 07, 2010–Apr. 06, 2011.
HFEA Code of Practice Edition 8—R.3 was in effect: Apr. 07, 2011–Oct.
01, 2011.
Embryo culture and micromanipulation
Embryo culture and laser-assisted dissection of inner cell mass
(ICM) were carried out as previously described in details (Ilic et al.,
2012; Stephenson et al., 2012). The cellular area containing the ICM
was then washed and transferred to plates containing mitotically
inactivated human neonatal foreskin ﬁbroblasts (HFF).
Cell culture
ICM plated on mitotically inactivated HFF were cultured as de-
scribed (Ilic et al., 2012; Stephenson et al., 2012). TE cells were re-
moved mechanically from outgrowth (Ilic et al., 2007; Ilic et al.,
2010). hESC colonies were expanded and cryopreserved at the third
passage.
Viability test
Straws with the earliest frozen passage (p.2–3) are thawed and
new colonies are counted 3 days later. These colonies are then ex-
panded up to passage 8, at which point cells were part frozen and
part subjected to standard battery of tests (pluripotency markers,
in vitro and in vivo differentiation capability, genetics, sterility,
mycoplasma).
Pluripotency markers
Pluripotencywas assessed using two different techniques: enzymat-
ic activity assay [alkaline phosphatase (AP) assay] and immunostaining
as described (Ilic et al., 2012; Stephenson et al., 2012).
Differentiation
Spontaneous differentiation into three germ layers was assessed
in vitro and in vivo (Jacquet et al., 2015) as described (Ilic et al., 2012;
Stephenson et al., 2012; Petrova et al., 2014). Targeted differentiation
in cardiomyocytes followed the protocols described earlier (Jacquet
et al., 2015; Laﬂamme et al., 2007).
Genotyping
DNA was extracted from hESC cultures using a Chemagen DNA
extraction robot according to the manufacturer's instructions.
Fig. 3. Differentiation of three germ layers in vitro is conﬁrmed by detection of markers: smooth muscle actin (ACTA2, red) for mesoderm, β-III tubulin (TUBB3, red) for ectoderm,
and α-fetoprotein (AFP, red) for endoderm. Nuclei are visualized with Hoechst 33342 (blue). Scale bar, 25 μm.
Fig. 2. Expression of pluripotency markers. Pluripotency is conﬁrmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Scale bar,
20 μm.
347L. Jacquet et al. / Stem Cell Research 16 (2016) 345–348Ampliﬁcation of polymorphic microsatellite markers was carried out as
described (Ilic et al., 2012). Allele sizes were recorded to give a unique
ﬁngerprint of each cell line.
Array comparative genomic hybridization (aCGH)
aCGH was performed as described in details (Ilic et al., 2012).
Special pathology
The Doctors Laboratory London (UK) tested the line for HIV1, HepB,
HepC, CMV, and EBV by PCR.Fig. 4. Differentiation of three germ layers in vivo. Teratomas were encapsulated and did not
speciﬁc stains are brown (immunohistochemistry). Germ layer marker: DES for mesoderm, TUAuthor disclosure statement
There are no competing ﬁnancial interests in this study.
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